Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Katharine L. Lewis"'
Autor:
Zhong Goh, Maya Latimer, Katharine L. Lewis, Chan Y. Cheah, Pietro Di Ciaccio, Tania Cushion, Eliza A. Hawkes, Sean Harrop, Matthew Ku, Ashlea Campbell, Nada Hamad, Erica M. Wood, Eliza Chung, Pin-Yen Chen, Tara Cochrane
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 23:370-378
Autor:
Zhong Goh, Maya Latimer, Katharine L. Lewis, Chan Yoon Cheah, Pietro Di Ciaccio, Tania Cushion, Eliza Hawkes, Sean Harrop, Matthew Ku, Ashlea Campbell, Nada Hamad, Erica M. Wood, Eliza Chung, Pin-Yen Chen, Tara Cochrane
Publikováno v:
Blood. 140:9413-9415
Autor:
Eliza Hawkes, Katharine L. Lewis, Nicole Wong Doo, Sushrut S. Patil, Hari P. Miskin, Peter Sportelli, Kathryn S. Kolibaba, Emmanuel Normant, Tejasvi Turpuseema, Chan Y. Cheah
Publikováno v:
Blood. 140:6599-6601
Autor:
Anna Santarsieri, Rory Bennett, David Hopkins, Katharine L. Lewis, Cecilia N Gyansah, Lisa Cooke, Sateesh K. Nagumantry, Nimish K. Shah, Chan Y. Cheah, Pamela McKay, Michael Dickinson, John F. Seymour, George A Follows
Publikováno v:
Blood. 140:9551-9553
Publikováno v:
American Society of Clinical Oncology Educational Book. :614-628
Mantle cell lymphoma is a rare B-cell non-Hodgkin lymphoma that is clinically and biologically heterogeneous. Risk stratification at the time of diagnosis is critical. One of the most powerful prognostic indices is the Mantle Cell Lymphoma Internatio
Autor:
Bilal Tariq, Ying C. Ou, Jennifer C. Stern, Vaibhav Mundra, Nicole Wong Doo, Patricia Walker, Katharine L. Lewis, Chester Lin, William Novotny, Srikumar Sahasranaman, Stephen Opat
Publikováno v:
Leukemialymphoma.
BTK inhibitor exposure increases significantly when coadministered with CYP3A inhibitors, which may lead to dose-related toxicities. This study explored the pharmacokinetics, efficacy, and safety of zanubrutinib when coadministered with moderate or s
Autor:
Amy A Kirkwood, Kate Cwynarski, Alex Smith, Cathy Burton, Matthew J. Ahearne, Nicola Gray, Mark Bishton, Maxine Lamb, Jahanzaib Khwaja, Graham P. Collins, Nicolas Martinez-Calle, Timothy M Illidge, Kate Manos, Katharine L Lewis, Eliza A Hawkes, Christopher P. Fox, Wendy Osborne, Caroline Shrubsole, Kim Linton, Ann Tivey
Publikováno v:
Advances in Therapy
Martinez-Calle, N, Kirkwood, A A, Lamb, M, Smith, A, Khwaja, J, Manos, K, Shrubsole, C, Gray, N, Lewis, K, Tivey, A, Bishton, M J, Hawkes, E, Ahearne, M J, Osborne, W, Collins, G P, Illidge, T, Linton, K M, Cwynarski, K, Burton, C & Fox, C P 2021, ' Systemic ALCL Treated in Routine Clinical Practice : Outcomes Following First-Line Chemotherapy from a Multicentre Cohort ', Advances in Therapy, vol. 38, no. 7, pp. 3789-3802 . https://doi.org/10.1007/s12325-021-01764-0
Martinez-Calle, N, Kirkwood, A A, Lamb, M, Smith, A, Khwaja, J, Manos, K, Shrubsole, C, Gray, N, Lewis, K, Tivey, A, Bishton, M J, Hawkes, E, Ahearne, M J, Osborne, W, Collins, G P, Illidge, T, Linton, K M, Cwynarski, K, Burton, C & Fox, C P 2021, ' Systemic ALCL Treated in Routine Clinical Practice : Outcomes Following First-Line Chemotherapy from a Multicentre Cohort ', Advances in Therapy, vol. 38, no. 7, pp. 3789-3802 . https://doi.org/10.1007/s12325-021-01764-0
Introduction Brentuximab vedotin (BV)-CHP is the new standard regimen for first-line treatment of systemic anaplastic large cell lymphoma (sALCL). We undertook a retrospective analysis of consecutive patients diagnosed with sALCL, treated in routine
Autor:
Jennifer A. Woyach, William G. Wierda, Catherine C. Coombs, Katharine L. Lewis, John G. Gribben, Maricer P. Escalon, Matteo Ceccarelli, Xiaoling Wu, Anthony R. Mato
Publikováno v:
Blood. 140:12427-12428
Autor:
Toby A Eyre, Kerry J Savage, Chan Y Cheah, Tarec C El-Galaly, Katharine L Lewis, Pamela McKay, Matthew R Wilson, Andrew M Evens, Sabela Bobillo, Diego Villa, Matthew J Maurer, Kate Cwynarski, Andrés J M Ferreri
Publikováno v:
Eyre, T A, Savage, K J, Cheah, C Y, El-Galaly, T C, Lewis, K L, McKay, P, Wilson, M R, Evens, A M, Bobillo, S, Villa, D, Maurer, M J, Cwynarski, K & Ferreri, A J M 2022, ' CNS prophylaxis for diffuse large B-cell lymphoma ', The Lancet Oncology, vol. 23, no. 9, pp. e416-e426 . https://doi.org/10.1016/S1470-2045(22)00371-0
CNS relapse in the brain parenchyma, eyes, or leptomeninges is an uncommon but devastating complication of diffuse large B-cell lymphoma. CNS prophylaxis strategies, typically involving intrathecal or high-dose antimetabolites, have been developed in
Autor:
Jonathon B. Cohen, Nirav N. Shah, Alvaro J. Alencar, James N. Gerson, Manish R. Patel, Bita Fakhri, Wojciech Jurczak, Xuan Ni Tan, Katharine L. Lewis, Timothy Fenske, Catherine C. Coombs, Ian W. Flinn, David J. Lewis, Steven Le Gouill, M. Lia Palomba, Jennifer A. Woyach, John M. Pagel, Nicole Lamanna, Minal A. Barve, Paolo Ghia, Toby A. Eyre, Pier Luigi Zinzani, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, Ewa Lech-Maranda, Constantine S. Tam, Suchitra Sundaram, Ming Yin, Binoj Nair, Donald E. Tsai, Minna Balbas, Anthony R. Mato, Chan Y. Cheah, Michael L. Wang
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S394-S395
Covalent BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL), but most patients will require additional treatment. Pirtobrutinib is a highly selective, non-covalent (reversible) BTKi that inhibits both wild-type and C4